Skip to main content
    T

    Travere Therapeutics Inc (TVTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $49.70
    -0.95 (-1.88%)

    Market Cap: $4.86B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Travere Therapeutics Inc (TVTX) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Travere Therapeutics (TVTX) trades at 7.2x sales and 208.2x book value. Its P/S of 7.2x is above its 5-year median of 6.6x. Its forward P/E is 25.1x.

    Current Multiples

    Its free cash flow yield is 1.9%.

    MultipleValue
    P/E (trailing)N/A
    Forward P/E25.1x
    Price to sales7.2x
    Price to book208.2x
    Price to FCF51.6x
    EV/FCF56.9x
    PEGN/A
    FCF yield1.9%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 22.0% above 5.9x and its P/B is 5238.5% above 3.9x.

    MultipleCurrent5-year median10-year median
    P/S7.2x6.6x5.9x
    P/B208.2x23.4x3.9x
    Medians of month-end values through Oct 2026: 57 to 60 months (5-year) and 117 to 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/S ranged from 3.4x in 2019 to 8.2x in 2021.

    Year endPriceP/EP/SP/B
    2025$38.2142.5x7.3x30.0x
    2024$17.42N/A5.9x24.5x
    2023$8.99N/A3.9x3.4x
    2022$21.03N/A7.2x31.5x
    2021$31.04N/A8.2x6.3x
    2020$27.26N/A6.5x6.6x
    2019$14.20N/A3.4x2.8x
    2018$22.63N/A5.6x2.9x
    2017$21.07N/A5.3x2.9x
    2016$18.93N/A5.3x2.4x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About TVTX

    What is TVTX's forward P/E ratio?

    Travere Therapeutics has a forward P/E ratio of 25.1x.

    Is TVTX stock overvalued?

    GNG's valuation label for TVTX is Undervalued.

    What is TVTX's price to sales ratio?

    Travere Therapeutics has a price to sales ratio of 7.2x.